Evidence map›Paper›PMID 36970071›Full record

ArticleOncoimmunology2023

Rs867228 in FPR1 accelerates the manifestation of luminal B breast cancer.

Vincent Carbonnier, Julie Le Naour, Thomas Bachelot, Erika Vacchelli, Fabrice André, Suzette Delaloge, Guido Kroemer

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncoimmunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. TheFrontiers in immunology · 2025
    Review
  3. The danger theory of immunity revisited.Nature reviews. Immunology · 2024
    Review
  4. Review
  5. Article
  6. Immunosurveillance in clinical cancer management.CA: a cancer journal for clinicians
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Vincent CarbonnierEquipe labellisée par la Ligue contrele cancer, Université de Paris, Sorbonne Université, Paris, France.
Julie Le NaourEquipe labellisée par la Ligue contrele cancer, Université de Paris, Sorbonne Université, Paris, France.
Thomas BachelotCentre Léon Bérard, Département de Cancérologie Médicale, Lyon, France.
Erika VacchelliEquipe labellisée par la Ligue contrele cancer, Université de Paris, Sorbonne Université, Paris, France.
Fabrice AndréUniversité Paris Saclay, Faculty of Medicine Kremlin Bicêtre, Le Kremlin Bicêtre, France.
Suzette DelalogeDepartment of Cancer Medicine, Gustave Roussy Cancer Campus, Villejuif, France.
Guido KroemerEquipe labellisée par la Ligue contrele cancer, Université de Paris, Sorbonne Université, Paris, France.ORCID 0000-0002-9334-4405
Université Paris Cité · FRCentre Léon Bérard · FRInserm · FRInstitut Gustave Roussy · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Formyl peptide receptor-1 (FPR1) is a pathogen recognition receptor involved in the detection of bacteria, in the control of inflammation, as well as in cancer immunosurveillance. A single nucleotide polymorphism in

Indexed as

Breast NeoplasmsCarcinomaReceptors, Formyl PeptideGenotypeHumansPhenotypePolymorphism, Single NucleotideFPR1 protein, humanReceptors, Formyl PeptideCancer screeningimmunodeficiencyimmunosurveillancemammary carcinomapolygenic risk score

Identifiers

PMID36970071
PMCPMC10038022
OpenAlexW4328100445

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.